Novartis says it is bringing Pluvicto, an advanced prostate cancer drug, to patients in India. The company describes Pluvicto as a radioligand therapy and states that it was the first such treatment in India to be approved by a regulatory authority for patients. Reporting on the launch centers on the therapy’s introduction and its regulatory status, rather than on clinical outcomes or pricing details. The information provided emphasizes that Pluvicto is the company’s product now available in the Indian market and highlights its position as the first regulatory-authority-approved radioligand therapy for patients in the country, according to Novartis India. Other aspects of the release, including eligibility criteria, rollout timelines, and treatment protocols, are not described in the available excerpts. The update therefore focuses primarily on availability and the stated regulatory milestone connected to the therapy’s entry into India.